Big Pharma

مستقر3 خبر2 مصادرآخر تحديث: 7 sa önce

أحدث الأخبار

Biotech IPO Window Reopens, But Big Pharma Acquisitions Remain Strong

The biotech IPO market is showing signs of recovery, but top dealmakers at JPMorgan suggest strong companies may still opt for acquisition by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies. This trend reflects a broader healthcare dealmaking rebound driven by Big Pharma's need to replenish pipelines.

CNBC World

Biopharma M&A Surges, Poised for Strongest Year Since 2019 Peak

يتطور

Business·04.06.2026ملخص الذكاء الاصطناعي

Biopharma M&A Surges, Poised for Strongest Year Since 2019 Peak

Global biopharma M&A is accelerating in 2026, driven by patent cliffs and pipeline needs. Dealmaking has reached $106 billion, on track to exceed $250 billion, the highest since 2019. Strategic 'bolt-on' acquisitions under $5 billion dominate, with a growing interest in Chinese assets.

CNBC World

MPs challenge Wes Streeting’s new powers over NHS drug pricing

يتطور

سياسة·26.04.2026ملخص الذكاء الاصطناعي

MPs challenge Wes Streeting’s new powers over NHS drug pricing

Thirty-one MPs have launched a parliamentary challenge against new powers granted to Health Secretary Wes Streeting, allowing him to dictate NHS drug spending thresholds. Critics argue the move undermines the independence of Nice and favors US pharmaceutical interests.

Guardian UK